Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin

Neurosurgical Focus

Volumn 41, Issue 6, 2016, Pages

  Stache, Christina ^a,b   Bils, Christiane ^a   Fahlbusch, Rudolf ^c   Flitsch, Jörg ^d   Buchfelder, Michael ^a   Stefanits, Harald ^e   Czech, Thomas ^e   Gaipl, Udo ^a   Frey, Benjamin ^a   Buslei, Rolf ^a   Hölsken, Annett ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INTERNATIONAL NEUROSCIENCE INSTITUTE   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adamantinomatous craniopharyngioma; EGFR; Radiation; Survivin; Tyrosine kinase inhibitor

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CRANIOPHARYNGIOMA; DOWN REGULATION; DRUG EFFECTS; FEMALE; HUMAN; HYPOPHYSIS TUMOR; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RADIATION RESPONSE; RADIATION TOLERANCE; TUMOR CELL CULTURE;

ADOLESCENT; ADULT; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CRANIOPHARYNGIOMA; DOWN-REGULATION; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROTEIN KINASE INHIBITORS; RADIATION TOLERANCE; TUMOR CELLS, CULTURED;

EID: 85002194582     PISSN: None     EISSN: 10920684     Source Type: Journal    
DOI: 10.3171/2016.9.FOCUS16316     Document Type: Article

References (73)

1. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC: Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 351:882-883, 1998.
2. Ai Z, Yin L, Zhou X, Zhu Y, Zhu D, Yu Y, et al: Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 107:746-756, 2006.
3. Altieri DC: Targeting survivin in cancer. Cancer Lett 332:225-228, 2013.
4. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917-921, 1997.
5. Asami K, Atagi S: Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer. World J Clin Oncol 5:646-659, 2014.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006.
7. Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ, Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol 108:370-377, 2013.
8. Buchfelder M, Schlaffer SM, Lin F, Kleindienst A: Surgery for craniopharyngioma. Pituitary 16:18-25, 2013.
9. Buslei R, Hölsken A, Hofmann B, Kreutzer J, Siebzehnrubl F, Hans V, et al: Nuclear b-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathol 113:585-590, 2007.
10. Caldas H, Honsey LE, Altura RA: Survivin 2a: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 4:11, 2005.
11. Chakravarti A, Dicker A, Mehta M: The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int J Radiat Oncol Biol Phys 58:927-931, 2004.
12. Darzynkiewicz Z, Juan G, Li X, Gorczyca W, Murakami T, Traganos F: Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1-20, 1997.
13. Dong Q, Sharma S, Liu H, Chen L, Gu B, Sun X, et al: HDAC inhibitors reverse acquired radio resistance of KYSE-150R esophageal carcinoma cells by modulating Bmi-1 expression. Toxicol Lett 224:121-129, 2014.
14. Erfurth EM, Holmer H, Fjalldal SB: Mortality and morbidity in adult craniopharyngioma. Pituitary 16:46-55, 2013.
15. Fahlbusch R, Honegger J, Paulus W, Huk W, Buchfelder M: Surgical treatment of craniopharyngiomas: experience with 168 patients. J Neurosurg 90:237-250, 1999.
16. Finzer P, Kuntzen C, Soto U, zur Hausen H, Rösl F: Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20:4768-4776, 2001.
17. Geoerger B, Gaspar N, Opolon P, Morizet J, Devanz P, Lecluse Y, et al: EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. Int J Cancer 123:209-216, 2008.
18. Hartmann J, Wölfelschneider J, Stache C, Buslei R, Derer A, Schwarz M, et al: Novel technique for high-precision stereotactic irradiation of mouse brains. Strahlenther Onkol [epub ahead of print], 2016.
19. Hau E, Shen H, Clark C, Graham PH, Koh ES, L McDonald K: The evolving roles and controversies of radiotherapy in the treatment of glioblastoma. J Med Radiat Sci 63:114-123, 2016.
20. He L, Hou M, Zhang J, Xu N, Chen P: [Subcellular localization of survivin in non-small cell lung cancer.] Ai Zheng 28:955-960, 2009 (Chinese).
21. Hölsken A, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R: Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling. Acta Neuropathol 119:631-639, 2010.
22. Hölsken A, Eyüpoglu IY, Lueders M, Tränkle C, Dieckmann D, Buslei R, et al: Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 112:205-215, 2006.
23. Hölsken A, Gebhardt M, Buchfelder M, Fahlbusch R, Blümcke I, Buslei R: EGFR signaling regulates tumor cell migration in craniopharyngiomas. Clin Cancer Res 17:4367-4377, 2011.
24. Hölsken A, Kreutzer J, Hofmann BM, Hans V, Oppel F, Buchfelder M, et al: Target gene activation of the Wnt signaling pathway in nuclear b-catenin accumulating cells of adamantinomatous craniopharyngiomas. Brain Pathol 19:357-364, 2009.
25. Hölsken A, Sill M, Merkle J, Schweizer L, Buchfelder M, Flitsch J, et al: Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol Commun 4:20, 2016.
26. Hölsken A, Stache C, Schlaffer SM, Flitsch J, Fahlbusch R, Buchfelder M, et al: Adamantinomatous craniopharyngiomas express tumor stem cell markers in cells with activated Wnt signaling: further evidence for the existence of a tumor stem cell niche? Pituitary 17:546-556, 2014.
27. Hu T, Li C: Convergence between Wnt-b-catenin and EGFR signaling in cancer. Mol Cancer 9:236, 2010.
28. Iannalfi A, Fragkandrea I, Brock J, Saran F: Radiotherapy in craniopharyngiomas. Clin Oncol (R Coll Radiol) 25:654-667, 2013.
29. Jiang G, Ren B, Xu L, Song S, Zhu C, Ye F: Survivin may enhance DNA double-strand break repair capability by up-regulating Ku70 in human KB cells. Anticancer Res 29:223-228, 2009.
30. Kami K, Doi R, Koizumi M, Toyoda E, Mori T, Ito D, et al: Downregulation of survivin by siRNA diminishes radioresistance of pancreatic cancer cells. Surgery 138:299-305, 2005.
31. Karavitaki N: Management of craniopharyngiomas. J Endocrinol Invest 37:219-228, 2014.
32. Karavitaki N, Cudlip S, Adams CB, Wass JA: Craniopharyngiomas. Endocr Rev 27:371-397, 2006.
33. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N: Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074, 1998.
34. Kitamura H, Torigoe T, Hirohashi Y, Asanuma H, Inoue R, Nishida S, et al: Nuclear, but not cytoplasmic, localization of survivin as a negative prognostic factor for survival in upper urinary tract urothelial carcinoma. Virchows Arch 462:101-107, 2013.
35. Kokunai T, Tamaki N: Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas. Jpn J Cancer Res 90:638-646, 1999.
36. Kokunai T, Urui S, Tomita H, Tamaki N: Overcoming of radioresistance in human gliomas by p21WAF1/CIP1 antisense oligonucleotide. J Neurooncol 51:111-119, 2001.
37. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84:1415-1420, 1994.
38. Lai CJ, Bao R, Tao X, Wang J, Atoyan R, Qu H, et al: CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity. Cancer Res 70:3647-3656, 2010.
39. Lee CH, Hung HW, Hung PH, Shieh YS: Epidermal growth factor receptor regulates b-catenin location, stability, and transcriptional activity in oral cancer. Mol Cancer 9:64, 2010.
40. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK: WHO Classification of Tumours of the Central Nervous System, Revised, ed 4. Lyon, France: International Agency for Research on Cancer, 2016.
41. Lu CD, Altieri DC, Tanigawa N: Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-1812, 1998.
42. Lu Z, Ghosh S, Wang Z, Hunter T: Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of b-catenin, and enhanced tumor cell invasion. Cancer Cell 4:499-515, 2003.
43. Marioni G, Agostini M, Bedin C, Blandamura S, Stellini E, Favero G, et al: Survivin and laryngeal carcinoma prognosis: nuclear localization and expression of splice variants. Histopathology 61:247-256, 2012.
44. McKenzie JA, Grossman D: Role of the apoptotic and mitotic regulator survivin in melanoma. Anticancer Res 32:397-404, 2012.
45. Mobahat M, Narendran A, Riabowol K: Survivin as a preferential target for cancer therapy. Int J Mol Sci 15:2494-2516, 2014.
46. Mortini P, Gagliardi F, Boari N, Losa M: Surgical strategies and modern therapeutic options in the treatment of craniopharyngiomas. Crit Rev Oncol Hematol 88:514-529, 2013.
47. Mull AN, Klar A, Navara CS: Differential localization and high expression of SURVIVIN splice variants in human embryonic stem cells but not in differentiated cells implicate a role for SURVIVIN in pluripotency. Stem Cell Res (Amst) 12:539-549, 2014.
48. Müller HL: Craniopharyngioma. Endocr Rev 35:513-543, 2014.
49. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139:271-279, 1991.
50. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci U S A 97:13103-13107, 2000.
51. Okamoto K, Okamoto I, Okamoto W, Tanaka K, Takezawa K, Kuwata K, et al: Role of survivin in EGFR inhibitorinduced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res 70:10402-10410, 2010.
52. O'Rourke DM, Kao GD, Singh N, Park BW, Muschel RJ, Wu CJ, et al: Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells. Proc Natl Acad Sci U S A 95:10842-10847, 1998.
53. Paduano F, Villa R, Pennati M, Folini M, Binda M, Daidone MG, et al: Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 5:179-186, 2006.
54. Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, et al: Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells. Oncogene 23:386-394, 2004.
55. Pollack IF, Stewart CF, Kocak M, Poussaint TY, Broniscer A, Banerjee A, et al: A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol 13:290-297, 2011.
56. Qi G, Tuncel H, Aoki E, Tanaka S, Oka S, Kaneko I, et al: Intracellular localization of survivin determines biological behavior in colorectal cancer. Oncol Rep 22:557-562, 2009.
57. Reichert S, Rödel C, Mirsch J, Harter PN, Tomicic MT, Mittelbronn M, et al: Survivin inhibition and DNA double-strand break repair: a molecular mechanism to overcome radioresistance in glioblastoma. Radiother Oncol 101:51-58, 2011.
58. Rödel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rödel F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 55:1341-1347, 2003.
59. Sahlberg SH, Spiegelberg D, Glimelius B, Stenerlöw B, Nestor M: Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells. PLoS One 9:e94621, 2014.
60. Saito T, Arifin MT, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, et al: Survivin subcellular localization in high-grade astrocytomas: simultaneous expression in both nucleus and cytoplasm is negative prognostic marker. J Neurooncol 82:193-198, 2007.
61. Schroeder JA, Adriance MC, McConnell EJ, Thompson MC, Pockaj B, Gendler SJ: ErbB-b-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas. J Biol Chem 277:22692-22698, 2002.
62. Schweizer L, Capper D, Hölsken A, Fahlbusch R, Flitsch J, Buchfelder M, et al: BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts. Neuropathol Appl Neurobiol 41:733-742, 2015.
63. Shimizu T, LoRusso PM, Papadopoulos KP, Patnaik A, Beeram M, Smith LS, et al: Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors. Clin Cancer Res 20:5032-5040, 2014.
64. Song H, Xin XY, Xiao F, Wang DT, Yue QH, Han X: Survivin gene RNA interference inhibits proliferation, induces apoptosis, and enhances radiosensitivity in HeLa cells. Eur J Obstet Gynecol Reprod Biol 136:83-89, 2008.
65. Stache C, Hölsken A, Schlaffer SM, Hess A, Metzler M, Frey B, et al: Insights into the infiltrative behavior of adamantinomatous craniopharyngioma in a new xenotransplant mouse model. Brain Pathol 25:1-10, 2015.
66. Ulfarsson E, Karström A, Yin S, Girnita A, Vasilcanu D, Thoren M, et al: Expression and growth dependency of the insulin-like growth factor I receptor in craniopharyngioma cells: a novel therapeutic approach. Clin Cancer Res 11:4674-4680, 2005.
67. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C: A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184:39-51, 1995.
68. Wang H, Gambosova K, Cooper ZA, Holloway MP, Kassai A, Izquierdo D, et al: EGF regulates survivin stability through the Raf-1/ERK pathway in insulin-secreting pancreatic b-cells. BMC Mol Biol 11:66, 2010.
69. Wang L, Zhang XM, Li Z, Liu XJ, Chai J, Zhang GY, et al: Overexpression of nuclear b-catenin in rectal adenocarcinoma is associated with radioresistance. World J Gastroenterol 19:6876-6882, 2013.
70. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM: WNT/b-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 104:618-623, 2007.
71. Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA: Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 103:15540-15545, 2006.
72. Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I: CD44 anchors the assembly of matrilysin/MMP-7 with heparinbinding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev 16:307-323, 2002.
73. Zhu J, You C: Craniopharyngioma: survivin expression and ultrastructure. Oncol Lett 9:75-80, 2015.